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Abstract
Background: The form(s) of amyloid-b peptide (Ab) associated with the pathology characteristic of Alzheimer’s
disease (AD) remains unclear. In particular, the neurotoxicity of intraneuronal Ab accumulation is an issue of
considerable controversy; even the existence of Ab deposits within neurons has recently been challenged by
Winton and co-workers. These authors purport that it is actually intraneuronal APP that is being detected by
antibodies thought to be specific for Ab. To further address this issue, an anti-Ab antibody was developed (MOAB-
2) that specifically detects Ab, but not APP. This antibody allows for the further evaluation of the early
accumulation of intraneuronal Ab in transgenic mice with increased levels of human Ab in 5xFAD and 3xTg mice.
Results: MOAB-2 (mouse IgG2b) is a pan-specific, high-titer antibody to Ab residues 1-4 as demonstrated by
biochemical and immunohistochemical analyses (IHC), particularly compared to 6E10 (a commonly used
commercial antibody to Ab residues 3-8). MOAB-2 did not detect APP or APP-CTFs in cell culture media/lysates
(HEK-APPSwe or HEK-APPSwe/BACE1) or in brain homogenates from transgenic mice expressing 5 familial AD (FAD)
mutation (5xFAD mice). Using IHC on 5xFAD brain tissue, MOAB-2 immunoreactivity co-localized with C-terminal
antibodies specific for Ab40 and Ab42. MOAB-2 did not co-localize with either N- or C-terminal antibodies to APP.
In addition, no MOAB-2-immunreactivity was observed in the brains of 5xFAD/BACE
-/- mice, although significant
amounts of APP were detected by N- and C-terminal antibodies to APP, as well as by 6E10. In both 5xFAD and
3xTg mouse brain tissue, MOAB-2 co-localized with cathepsin-D, a marker for acidic organelles, further evidence for
intraneuronal Ab, distinct from Ab associated with the cell membrane. MOAB-2 demonstrated strong intraneuronal
and extra-cellular immunoreactivity in 5xFAD and 3xTg mouse brain tissues.
Conclusions: Both intraneuronal Ab accumulation and extracellular Ab deposition was demonstrated in 5xFAD
mice and 3xTg mice with MOAB-2, an antibody that will help differentiate intracellular Ab from APP. However,
further investigation is required to determine whether a molecular mechanism links the presence of intraneuronal
Ab with neurotoxicity. As well, understanding the relevance of these observations to human AD patients is critical.
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Background
The form(s) of amyloid-b peptide (Ab), particularly the 42
amino acid form (Ab42), associated with the neurotoxicity
characteristic of Alzheimer’s disease (AD) remains unclear.
The potential toxic assemblies of the peptide include
soluble Ab [1], oligomeric Ab [2], intraneuronal Ab [3]
and specific plaque morpholo g y[ 4 ] .E v i d e n c ei n d i c a t e s
that intraneuronal Ab accumulation may be an important
proximal neurotoxic event in AD pathogenesis (reviewed
in [5,6]). Studies suggest intraneuronal Ab accumulation
in AD [7-9] and Down’s Syndrome patients [10,11].
However, the relationship between intraneuronal Ab and
plaque deposition remains unclear. Evidence suggests that
intraneuronal Ab may precede extracellular plaque deposi-
tion in the brains of AD patients [12,13]. In particular,
intraneuronal Ab42 accumulates in AD susceptible brain
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and neurofibrillar tangle formation [3]. The “inside-out”
hypothesis posits that the intraneuronal Ab remaining
after neuronal apoptosis serves as seeds for amyloid pla-
ques. This is supported by several human studies demon-
strating that increasing plaque deposition corresponds to
decreased intraneuronal Ab staining [8,9]. However,
beyond this temporal sequence, the functional connection
between the deposition of Ab in neurons and the parench-
yma has not been established in human brain.
To further investigate intraneuronal Ab,a t t e n t i o nh a s
focused on analysis of transgenic mice with increased levels
of human Ab (Ab-Tg mice). In accordance with data from
AD patients, intraneuronal Ab precedes plaque deposition
in multiple Ab-Tg mouse models ([14-23]) and may
decrease as plaque deposition increases ([17,19,22,24]).
Importantly, clearance of intraneuronal Ab via immu-
notherapy reversed cognitive deficits in triple-transgenic
(3xTg mice) mice that harbor the PS1M146V,A P P Swe and
tauP301L transgenes [14,19]. Furthermore, after termination
of immunotherapy, intraneuronal Ab re-appears prior to
extracellular plaque deposition [20]. Intraneuronal Ab is
also associated with impaired long-term potentiation
(LTP), cognitive deficits and eventual neuronal loss in
Ab-Tg mouse models ([14,15,17-19]).
However, the neurotoxicity of intraneuronal Ab accu-
mulation is an issue of considerable controversy; indeed
even the existence of Ab deposits within neurons is cur-
rently subject to debate and interpretation http://www.
alzforum.org/res/for/journal/detail.asp?liveID=193. Con-
cern centers on whether the detected intraneuronal
immunoreactivity is the result of Ab antibodies binding
to APP [16]. Recently, Winton and co-workers used
3xTg mice to demonstrate intraneuronal immunodetec-
tion with the commonly used commercial antibodies
6E10 (residues 3-8 of Ab), 4G8 (residues 17-24 of Ab)
and 22C11 (N-terminal APP residues 66-81), but not
with C-terminal Ab40- and 42-specific antibodies [25].
This staining pattern was unchanged in the absence of
Ab (3xTg/b-secretase (BACE)
-/- mice), suggesting the
intraneuronal staining represents APP and not Ab.
These data are in stark contrast to multiple publications
demonstrating intraneuronal Ab staining in 3xTg mice
and other Ab-Tg mice [14,19,20,26].
These issues highlight experimental considerations that
need to be addressed in order to investigate intraneuro-
nal Ab accumulation in vivo.F i r s t ,a st h ec o n f o r m a t i o n
or conformations of intraneuronal Ab is not known, the
detection of intraneuronal Ab it is likely to be optimal
with a pan-specific antibody that detects different confor-
mations of Ab. Second, antibodies must be specific for
Ab and not detect APP. Thus, intraneuronal Ab cannot
be specifically identified by antibodies directed against
residues 3-8 (e.g. 6E10), and residues 17-24 (e.g. 4G8) of
Ab because these antibodies also recognize full length
APP [16] and APP C-terminal fragments (APP-CTFs)
[27-30]. This is particularly relevant for Ab-Tg mouse
models that express high levels of the APP transgene (e.g.
2 and ~5 fold higher in the brains of the hemizygous and
homozygous 3xFAD mice than endogenous APP in wild-
type (WT) mice [19]). Third, the detection of intraneuro-
nal Ab in Ab-Tg mouse models can be confirmed by
genetic or pharmacological approaches. For example, in
Tg-ArcSwe/BACE1
-/- mice and Tg-ArcSwe mice treated
with a g-secretase inhibitor, no intraneuronal Ab was
detected with antibody 82E1 (Ab residues 1-5) and
Ab42- and Ab40-specific antibodies [31]. Fourth, co-
localization with an intraneuronal organelle marker
would provide further evidence for Ab pathology exists
within a neuron, distinct from Ab associated with the cell
membrane or in the extracellular space.
Due to this cross reactivity of anti-Ab antibodies with
APP, a mouse monoclonal antibody (MOAB-2, IgG2b)
was developed that is specific for Ab and does not detect
APP. MOAB-2 is a pan-specific monoclonal antibody that
recognizes unaggregated (U), oligomeric (O), and fibrillar
(F) forms of synthetic Ab42, as well as unaggregated
Ab40. MOAB-2 did not detect APP or APP-CTFs in cell
culture media/lysates (HEK-APPSwe or HEK-APPSwe/
BACE1) or in brain homogenates from transgenic mice
expressing 5 FAD mutations (5xFAD mice) [18]. By
immunohistochemistry (IHC) analysis of 5xFAD brain tis-
sue, MOAB-2 co-localized with Ab40- and 42 C-terminal
specific antibodies, but does not co-localize with N- or
C-terminal APP antibodies. No MOAB-2 immunoreactiv-
ity was observed in the brains of 5xFAD/BACE
-/- mice
although significant amounts of APP were detected with
anti-APP antibodies as well as by 6E10. In both 5xFAD
and 3xTg mouse tissue, MOAB-2 co-localized with cathe-
psin-D, a marker for acidic organelles, providing further
evidence for specifically identifying intraneuronal Ab.I n
addition, MOAB-2 demonstrated strong intraneuronal
and extra-cellular immunoreactivity in 5xFAD and 3xTg
brain tissue.
Results
Biochemical characterization: Identifying the MOAB-2
epitope on Ab
Peptide arrays consisting of a series of overlapping 10-
mers from the -4 position of the Ab sequence to residue
46 were used to identify the epitope of MOAB-2 (Addi-
tional file 1: Figure S1A). Using these membranes,
MOAB-2 detection was exclusive to residues 1-6, as this is
the only sequence common to the 5 overlapping 10-mers
detected by MOAB-2. As shown, the IgG2b negative con-
trol was blank.
Taking advantage of the sequence difference between
human and rat/mouse Ab, which includes a difference
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MOAB-2 epitope was further refined to residues 1-4 of
Ab (Additional file 1: Figure S1B). By Dot blot, MOAB-
2 detected rat Ab40 and human Ab40, albeit with less
affinity than for Ab42 (discussed below). The sequence
for rat Ab and human Ab40 are given below, with the
differences at positions 5, 10 and 13 in bold.
Rat Ab: DAEFGHDSGFEVRHQKLVFFAEDVGSN
KGAIIGLMVGGVV
Human Ab: DAEFRHDSGYEVHHQKLVFFAEDVGSN
KGAIIGLMVGGVV
Biochemical characterization: MOAB-2 detects Ab40 and
multiple conformations of Ab42 at low antigen and
antibody concentrations
Recent research indicates that the role of Ab42 in neuro-
toxicity may be dependent on the conformation of the
peptide aggregates. Thus, to investigate Ab accumulation
in vivo, it is useful for an anti-Ab antibody to detect multi-
ple assembly states Ab but not APP. Previously, an assem-
bly protocol was optimized to produce preparations
enriched in unaggregated (U), oligomeric (O), and fibrillar
(F) forms of synthetic Ab42 [32]. Under the conditions of
this protocol, Ab40 remained unaggregated. As assessed
by dot blot (Figure 1A), MOAB-2 detects preparations
enriched in U-, O-, F-Ab42, and U-Ab40 [32,33], and is
thus a pan-specific Ab antibody. However, MOAB-2 is
selective for the more neurotoxic Ab42 compared to
Ab40. Indeed, MOAB-2 demonstrated a titration against
antigen concentration, and detects Ab40 at 2.5 pmol but
U-, O- and F-Ab42 at antigen concentrations as low as
~ 0.1 pmol (Figure 1A). The commercial Ab antibody
6E10 (antibody to residues 3-8 of Ab appeared less selec-
tive for Ab42 vs. Ab40 but exhibited antigen detection of
Ab42 comparable to MOAB-2 (Figure 1A). In addition to
antigen concentration, MOAB-2 demonstrated an anti-
body-dependent saturation curve (Figure 1B) to a fixed
amount of immobilized U-, O- or F-Ab42 (25 ng). The
EC50 values for MOAB-2 were not significantly different
for U-, O- or F-Ab42 conformations (13, 12 and 18 ng/ml
respectively).
The ability of MOAB-2 to detect different molecular
weight Ab assemblies was assessed via Western blot
analysis of proteins separated by SDS-PAGE. Given the
apparent selectivity of MOAB-2 for Ab42 versus Ab40,
5-fold greater Ab40 (1000 pmol) than Ab42 (200 pmol)
was loaded for comparable detection with MOAB-2.
MOAB-2 and 6E10 identified bands corresponding to
the size of Ab42 monomer, trimer and tetramer with U-
Ab42 (Figure 1C). Ab40 was predominantly monomeric,
with a minor band consistent with tetramer detected
with MOAB-2. In contrast, 6E10 detection of Ab40 (200
pmol) and U-Ab42 (200 pmol) was comparable. To
further assess sensitivity of MOAB-2 and 6E10, U-, O-
and F-Ab42 conformations were analyzed again by
Western analysis using a wide range of antibody con-
centrations (500-5 ng/ml) (Figure 1D, left). MOAB-2
titrates with antibody concentration and multiple Ab42
conformations were detected at MOAB-2 concentrations
of 5 ng/ml. While 6E10 detected Ab42 over the same
antibody dilution range, the signal intensity was lower
than MOAB-2. Comparing the optical densities of the 3
antibody dilutions using MOAB-2 and 6E10 highlights
this difference (Figure 1D, right). In addition, immuno-
precipitation with MOAB-2 resulted in a high recovery
of Ab42 (Figure 1E), equivalent to more than 10% of
total input for both U- and O-Ab42, and significantly
higher than that of 6E10.
Biochemical characterization: MOAB-2 does not detect
APP/APP-CTFs in cell culture media and lysates or cortical
brain extracts from 5xFAD mice
A major issue for detecting Ab in vitro and in vivo is that
some Ab antibodies recognize APP or C-terminal frag-
ments of APP (APP-CTFs) [34-36]. Therefore to assess
cross-reactivity of MOAB-2 with APP and APP-CTFs,
HEK cells co-transfected to express APPSwe and BACE1
(HEK-APPSwe/BACE1) were used as these cells produce a
substantial amount of APP-CTFs (Figure 2A) [37]. Wes-
tern analysis demonstrates that an APP C-terminal anti-
body (CTF1565), 22C11 and 6E10 detect a ~100 kDa band
consistent with APP, while MOAB-2 does not (Figure 2A).
Importantly, CTF1565 and 6E10 also recognize ≤ 15 kDa
bands consistent with APP-CTFs, while MOAB-2 does
not.
To confirm that MOAB-2 does not recognize APP in
brain homogenates, 5xFAD mouse cortex was extracted
with 1% Triton X-100 [38], run on SDS-PAGE and ana-
lyzed by Western blot with 6E10 and MOAB-2 (Figure
2B). 6E10 detected a protein with a molecular weight con-
sistent with APP that was not recognized by MOAB-2.
Immunohistochemical (IHC) analysis: Staining in 5xFAD
brain sections
Initially, to determine whether MOAB-2 would be effec-
tive at detecting Ab by IHC, coronal sections of the frontal
cortex from 1- and 3-month old 5xFAD mice [18] were
immunostained with 6E10 and MOAB-2 and visualized
via DAB staining (Figure 2C). In the frontal cortices of
these mice at 1-month of age, 6E10 is strongly immunor-
eactive across the field of the cortex, while higher magnifi-
cation shows that the cytoplasm is evenly stained with an
immunonegative nuclei. In contrast, MOAB-2 staining of
the cortical field is substantially less than for 6E10 and the
intraneuronal staining is punctate (Figure 2C). These
results are consistent with 6E10 detection of APP and Ab,
and MOAB-2 recognition of only Ab.I n3 - m o n t ho l d
mice, extensive MOAB-2 immunopositive extracellular
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Higher magnification reveals low levels of MOAB-2 intra-
neuronal immunoreactivity with significant staining of
individual plaques. As intraneuronal MOAB-2 immunor-
eactivity was detected at 1-month of age in 5xFAD mice,
this age was used for subsequent experiments to deter-
mine the specificity of MOAB-2.
IHC analysis: MOAB-2 detection of intraneuronal Ab but
not intraneuronal APP in 5xFAD brain tissue
For IHC detection of intraneuronal Ab, the specificity of
MOAB-2 for Ab and APP was determined using immu-
nofluorescent confocal microscopy. Coronal sections of
the frontal cortex from 1-month old 5xFAD mice were
co-immunostained with MOAB-2 and Ab42- or Ab40-
specific antibodies (Figure 3A). Both the Ab42- and
Ab40-specific antibodies demonstrate punctate intra-
neuronal immunoreactivity that co-localized with
MOAB-2. Thus, MOAB-2 appears to detect intraneuro-
nal Ab.
To determine whether MOAB-2 staining cross-reacted
with APP, coronal sections of the frontal cortex from
1-month old 5xFAD mice were co-stained MOAB-2 or
22C11 (N-terminus of APP) or CT695 (C-terminus of
APP). MOAB-2 staining was punctate and did not co-
localize with either APP antibodies (Figure 3B). The speci-
ficity of MOAB-2 for Ab was confirmed via a genetic
approach, utilizing brain tissue from 5xFAD/BACE
-/- mice
that produce APP but not Ab (Figure 3C). Significant
immunoreactivity was observed with 22C11 and CT695,
while no immunoreactivity was observed with MOAB-2 in
the cortex of 4-month old animals. In contrast, 6E10
Figure 1 MOAB-2 detects multiple Ab conformations at low antibody concentrations. (A) Dot blot of serial Ab40 (unaggregated) and
Ab42 dilutions (unaggregated (U), oligomeric (O) or fibrillar (F)) probed with MOAB-2 or 6E10. (B) Antibody-binding saturation curve of 25 ng
Ab42 in the different aggregation states (U, O, and F) immobilized on microtiter plates, incubated with different MOAB-2 concentrations as
indicated on figure. (C) Western-blot analysis of 1000 pmol U-Ab40 or 200 pmol U-Ab42 probed with MOAB-2 (lanes 1-2) or 200 pmol U-Ab40
and U-Ab42 probed with 6E10(lanes 3-4). (D) Western-blot analysis comparing antibody dilutions of MOAB-2 and 6E10 (0.5 mg/ml antibody
stock concentrations) using U-, O- and F-Ab42 (200 pmol). Quantification of Ab immunoreactivity for each antibody dilution estimated using
image J. (E) Immunoprecipitation of U- and O-Ab42 (0.5 pmol) with 6E10 or MOAB-2 (Lane 1 = IP-6E10, 2 = IP-MOAB-2, 3 = 5% total input
(0.025 pmol), 4 = 10% total input (0.05 pmol). The dilution of MOAB-2 for Figures 1A and C is 1:5000 from a stock of 0.5 mg/ml.
Youmans et al. Molecular Neurodegeneration 2012, 7:8
http://www.molecularneurodegeneration.com/content/7/1/8
Page 4 of 14immunoreactivity co-localized with CT695, confirming
6E10 detection of APP.
IHC analysis: MOAB-2 co-localization with cathepsin-D in
5xFAD and 3xTg brain tissue
Overall, the in vitro or in vivo data presented in Figures 1,
2, 3 demonstrate that MOAB-2 detects Ab but not APP.
In particular, intraneuronal MOAB-2 immunoreactivity
is consistent with Ab and does not appear to be due to
cross-reactivity with APP. In cortical tissue from
1-month old 5xFAD (Figure 4A) and 6-month old 3xTg
(Figure 4B) mice, MOAB-2 co-localized with cathepsin-
D, a marker for lysosomes and other acidic organelles.
Co-localization of MOAB-2 with an intracellular orga-
nelle marker provides further evidence of Ab localization
within a neuron, distinct from Ab associated with the cell
membrane or in the extracellular space. The majority of
cells in the cortex were cathepsin-D immunopositive, as
expected, whereas fewer cells were immunopositive for
MOAB-2. In the cells that contained intraneuronal Ab,
while the majority of the cathepsin-D co-localized with
MOAB-2, some cathepsin-D staining did not co-localize,
consistent with not all lysosomes containing Ab.
IHC analysis: MOAB-2 detection of intraneuronal Ab and
extracellular plaques in 5xFAD and 3xTg mouse brain
tissue
Previous studies have demonstrated that intraneuronal Ab
accumulates prior to extracellular plaque deposition and
decreases as plaque deposition increases. However, if the
Ab antibodies also detect APP, interpretation of the results
can be problematic, as recently questioned by Winton and
co-workers [25]. Compared to other Ab-Tg mice such as
5xFAD mice (reviewed [39]), this concern is particularly
relevant to the 3xTg mice as prominent intraneuronal Ab
staining is observed for an extended period of time,
approximately 4- to 18-months [19]. As MOAB-2 detects
intracellular Ab and not APP, the progression of Ab
Figure 2 MOAB-2 does not detect APP in cell culture media and lysates or cortical brain extracts from 5xFAD mice. (A) Western-blot
analysis of 5 μgo r1 5μg cell lysates from HEK-APPSwe/BACE1 cells, probed with antibodies against C-terminus of APP (CT1565), N-terminus of
APP (2211), Ab (6E10, MOAB-2) or b-Actin (loading control). (B) Western analysis of 25 μg total protein from detergent-extracted 5xFAD mouse
cortex probed with 6E10 or MOAB-2 and b-Actin for loading control. (C) DAB staining with 6E10 or MOAB-2 in 1- and 3-month old 5xFAD mice.
Box insert: single neuron staining (Coronal sections, top = 10x scale, bar 100 μm; bottom = 100x, scale bar 20 μm). The dilution of MOAB-2 for
Figures 2A,B and C is 1:5000 from a stock of 0.5 mg/ml. (See “Dot- and Western-blot Analyses” in Methods for other antibody concentrations.).
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5xFAD and 3xTg mice (Figures 5A and 5B, respectively).
5xFAD mice exhibit accelerated Ab pathology, with intra-
neuronal Ab increased from 1- to 2-months and decreased
by 4-months, while plaque deposition increased from 2- to
4-months. To ‘match’ the progression of Ab pathology
with 5xFAD mice, tissue sections from 4-, 8- and
24-month old 3xTg mice were stained with MOAB-2.
Intraneuronal Ab increased from 4- to 8-months and
decreased by 24-months, while extracellular Ab increased
from 8- to 24-months. Intraneuronal Ab deposition in the
3xTg mice is present over a broad age range prior to the
deposition of extracellular Ab. Thus 3xTg mice represent
a model of Ab pathology with intraneuronal the major site
for accumulation of Ab.
Discussion
The identification of Ab as the major component of amy-
loid plaques has led to the amyloid cascade hypothesis and
the idea that reducing plaques would correlate with a
reduction in AD symptoms [40]. However plaque load as
detected post-mortem does not correlate with cognitive
impairment pre-mortem (reviewed [41]). The amyloid cas-
cade hypothesis has been modified [42], as attention
shifted to soluble oligomeric Ab conformations as the
toxic form of the peptide. Soluble oligomeric Ab has been
detected from brain tissue [43] and demonstrated to corre-
late with cognitive deficits in AD patients (reviewed
[41,44,45]). Oligomeric assemblies, including protofibril,
annular assembly, 56* and dimer/trimers induce neuro-
toxicity in vitro and in vivo (reviewed [41,44,45]). While it
is most likely that soluble Ab assemblies and insoluble
amyloid are in a form of dynamic equilibrium, it remains
essential to consistently perform Ab analyses in vitro and
in vivo. MOAB-2 is a pan-specific monoclonal antibody
(Ab residues 1-4) that detects several conformational spe-
cies of Ab42 with high affinity via dot and Western blot,
immunoprecipitates Ab with a higher recovery compared
to 6E10, and does not detect APP in cell culture lysates
and brain homogenates from 5xFAD tissue. In addition to
biochemical analysis, IHC staining with MOAB-2 demon-
strates robust and specific intracellular Ab immunoreac-
tivity at low antibody concentrations in both 5x5AD and
3xTg mice.
In 3xTg mice, Winton and co-workers demonstrated
intraneuronal APP detection by APP N- and C-terminal
specific antibodies, as well as 6E10 and 4G8, in agreement
with this study in 5xFAD mice. As 6E10 and 4G8 continue
to be used to identify Ab, both biochemically [46] and by
IHC [27,47-49], these results underscore the importance
of using antibodies that have been carefully characterized.
MOAB-2 did not co-localize with either N- or C-terminal
antibodies to APP, and MOAB-2-immunreactivity was not
observed in the brains of 5xFAD/BACE
-/- mice, although
significant amounts of APP were detected by N- and
C-terminal antibodies to APP, as well as by 6E10. Winton
and co-workers further conclude that intraneuronal Ab
cannot be detected using a panel of antibodies to the C-
terminus of Ab. However, confocal analysis with MOAB-2
demonstrated intraneuronal Ab detection that co-localized
with Ab40- and Ab42-specific antibodies, suggesting
Figure 3 MOAB-2 detection of intraneuronal Ab but not
intraneuronal APP in 5xFAD brain tissue. Immunofluorescent
detection of Ab and APP in the cortex of: (A) 1-month old 5xFAD
mice using: MOAB-2, Ab42- or Ab40-specific antibodies; (B) 1-month
old 5xFAD mice with MOAB-2 and antibodies against the C-
terminus (Cter) (CT695) or N-terminus (Nter) (2211) of APP; and (C)
4-month old 5xFAD/BACE
-/- with 6E10 or MOAB-2, plus antibodies
CT695 and 22C11. (Coronal sections, representative confocal images
at 100x). Antibody concentrations: MOAB-2 (1:1000), anti-Ab40,
(1:1700), anti-Ab42 (1:200), 22C11 (1:40), CT695 (1:500), 6E10 (1:1000).
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dies. While these differences could simply be due to the
strain of transgenic mice (5xFAD versus 3xTg) or some
unique Ab epitope present in intraneuronal Ab in 5xFAD
mice, MOAB-2 co-localized with cathepsin-D, providing
further evidence for the presence of intraneuronal Ab.I n
addition, MOAB-2 demonstrated strong intraneuronal
and extra-cellular immunoreactivity as pathology devel-
oped in the 5xFAD (1-4 months) and 3xTg (2-24 months)
mouse brain tissue. This extracellular staining in the 3xTg
mice is consistent with the study by Winton. Thus, the
apparent differences between these two studies have no
simple explanation. Contributing factors could include the
method of microscopy, the panel of antibodies used, as
well as genetic drift in both the transgenic mouse lines,
3xTg mice (F. LaFerla, personal communications) and
5xFAD mice, if not maintained by breeding 5xFAD hemi-
zygous males with B6SJL F1 hybrid females (R. Vassar,
personal communications; unpublished observations MJ
LaDu and D. Hartley).
Intraneuronal Ab accumulation is re-emerging as an
important neurotoxic event in AD pathogenesis (reviewed
in [39,50]). Reports from the early 1980’s first described
intraneuronal Ab immunoreactivity in AD patients and
non-demented control subjects [12,13]. However, this
detection was assumed to represent cross reactivity with
Figure 4 MOAB-2 co-localization with cathepsin-D in 5xFAD and 3xTg mouse brain tissue. Immunofluorescent detection of intraneuronal
Ab with MOAB-2 and an antibody against cathepsin-D (1:50 dilution) in the cortex of: (A) 1-month old 5xFAD mice; and (B) 6-month old 3xTg
mice. (Coronal sections, representative confocal images at 100x).
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tissue using Ab42- or Ab40-specific antibodies demon-
strated intraneuronal Ab immunoreactivity [7-9,51].
Further data demonstrates that Ab aggregation can be
initiated intracellularly, is primarily Ab42 and accumulates
in AD-susceptible brain regions, including the entorhinal
cortex and hippocampus of AD patients compared to con-
trol subjects [7-9,51-53]. In humans, intraneuronal Ab
likely exists in a dynamic equilibrium with extracellular
Ab. The ‘inside-out’ hypothesis posits that some extracel-
lular amyloid is seeded by the intraneuronal Ab that
remains following neuronal apoptosis [7-9,51].
Data from Ab-Tg mouse models also support intra-
neuronal Ab as is a potentially important component of
AD pathology. Indeed, intraneuronal Ab42 appears to
cause neurodegeneration in transgenic mice expressing
Ab specifically targeted to the endoplasmic reticulum
[54]. Consistent with the inside-out hypothesis,
Figure 5 MOAB-2 detection of intraneuronal Ab and extracellular plaques in 5xFAD and 3xTg mouse brain tissues. Immunofluorescent
detection of Ab with MOAB-2 in the subiculum of (A) 1-, 2- and 4-month old 5xFAD mice and (B) 4-, 8- and 24-month old 3xTg mice. (Coronal
sections, representative fluorescent images, top = 20x, scale bar 50 μm; bottom = 63x, scale bar 20 μm).
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tion in multiple Ab-Tg mouse models including Tg2576
[21], APPSL/ P S 1[ 2 3 ] ,3 x T g[ 1 4 , 1 9 ] ,5 x F A D[ 1 8 ] ,T g -
ArcSw [17] and APP/PS1KI [15], and as extracellular
deposition increases, intraneuronal Ab decreases
[17,19,22,24]. A significant portion of data reporting
accumulation and functionality of intraneuronal Ab ori-
ginates from the 3xTg mouse model. In 3xTg mice,
intraneuronal accumulation is present at 3- to 4-
months, persists until at least 12-months, and decreases
from 12- to 18-months, as extracellular deposition
increases from 6- to 24-months [14,19,26]. Therefore,
3xTg mice represent a model of substantial and sus-
tained intraneuronal Ab pathology. Indeed, after immu-
notherapy in 3xTg mice, intraneuronal Ab reappears
prior to extracellular plaque deposition [14,19,26] and
levels of intraneuronal Ab are associated with deficits in
LTP [19] and cognitive impairment [14,19,26].
Despite the evidence demonstrating intraneuronal Ab
accumulation in both human AD patients and in Ab-Tg
mouse models, it remains unclear the extent to which
intraneuronal Ab contributes to neurodegeneration. In
human tissue, detection of intraneuronal Ab immunoreac-
tivity is intermittent and not always associated with other
measures of Ab pathology [16]. In addition, the accumula-
tion of intraneuronal Ab during normal brain aging
remains an unresolved issue because Ab antibodies can
cross react with APP and other APP metabolites [55]. If
intraneuronal Ab is not a significant event in human AD
pathology, then the relevance of intraneuronal Ab accu-
mulation in Ab-Tg mice is uncertain. Other elements spe-
cific to a particular Ab-Tg mouse model may modulate
neurotoxicity, making it difficult to assign causality to
intraneuronal Ab. For example, combinations of FAD
mutations in APP and PS1 (and TauP301L), and temporal
links among multiple measures of pathology are two
examples of interactions that prevent identification of fac-
tors specifically correlating with neurotoxicity [25,56,57].
Thus, the functional connection between intraneuronal
Ab deposits and neurodegeneration warrants further
study, particularly in human subjects, both control and
AD patients. Reagents such as MOAB-2 will facilitate
future investigations.
Conclusions
Although the importance of intraneuronal Ab to AD
pathology remains unclear, the ability to consistently
detect these deposits with an Ab-specific antibody is cri-
tical. MOAB-2 is specific for Ab and demonstrates robust
intraneuronal immunoreactivity in vivo.T h u s ,M O A B - 2
has the potential to facilitate future investigations into
the importance of intraneuronal Ab, both in Ab-Tg
mouse models and human subjects.
Methods
Preparation of Ab peptide
Ab40 and Ab42 peptides (California Peptide NAPA, CA)
were prepared as previously described [32,33]. Briefly, the
peptides were monomerized by dissolving to a final con-
centration of 1 mM in hexafluoroisopropanol (HFIP)
(Sigma-Aldrich, St. Louis, MO), aliquoted into microcen-
trifuge tubes, the HFIP evaporated using a SpeedVac and
the peptide was stored at -20°C until use. For assembly
protocols, peptides were resuspended in dimethylsulfox-
ide (DMSO) to 5 mM and diluted to 100 μMi np h e n o l
red-free F12 media (BioSource, Camarillo, CA) for U-
and O-Ab42, or 10 mM HCL for F-Ab42 assemblies,
respectively. U-Ab42 was freshly prepared just prior to
use, O-Ab42 preparations were aged for 24 hours at 4°C
and F-Ab42 preparations for 24 hours at 37°C. Pre-
viously, assembly protocols were optimized to produce
preparations enriched in unaggregated, oligomeric or
fibrillar forms of synthetic Ab42. Under the conditions of
this protocol, Ab40 remained unaggregated [32].
Rat Ab40 (Calbiochem, San Diego, CA) was resus-
pended in DMSO to 1 mM, and diluted to 100 μMi n
phenol red-free F12 media just prior to use.
MOAB-2 generation
As previously described [58,59], female BALB/c mice were
immunized with O-Ab42 produced as outlined above.
For the initial injection, the immunogen was suspended in
200 μl Complete Freund’s Adjuvant at a concentration of
1 μg/μl. Subsequent subcutaneous injections of 200 μg
immunogen in Incomplete Freund’sA d j u v a n tw e r ec a r r i e d
out until the serum titer of the mouse was half-maximal at
a dilution of 2 × 10
-4 as judged by ELISA, with 50 ng of
O-Ab42 attached per well in the solid phase. Once the
desired serum titer was attained, immune spleens were
removed from the mice, dissociated, and fused with SP2/o
myeloma cells. The resultant cell suspension was plated in
96 well plates, HAT selected and cultured for 10-14 days to
allow clonal growth using standard hybridoma technology
previously described [58-60]. Initial clonal selection was
performed by antigen/antibody blotting. 5 mM O- or
F-Ab42 were incubated with Immobilon-P membrane at
room temperature for 30 min. Following rinsing and block-
ing, hybridoma supernatant was spotted onto membrane
with 96-pin replicator. Clonal supernatants from O-Ab42-
immunized mice that were positive on the O- membrane
and F-Ab42 membrane were selected for further subclon-
ing. Mother clones were subcloned 3-4 times to assure
monoclonality and to allow hybrids to stabilize. Antibodies
were isotyped and the stable clones adapted to serum-free
medium and placed in a bioreactor for antibody expression.
Monoclonal antibodies were then purified to homogeneity
using standard methods prior to storage at 1 mg/ml or
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[58-60]. MOAB-2 (IgG2b) was a high titer antibody identi-
fied by this process.
Source of antibodies
For the methods used in this study, the following primary
antibodies were utilized: MOAB-2 (anti-Ab, mouse IgG2b,
0.5 mg/ml), IgG2b (0.2 mg/ml, Sigma-Aldrich, St. Louis,
MO), 6E10 anti-Ab residues 3-8, mouse IgG1, 0.5 mg/ml;
Covance, Princeton, NJ), 22C11 (anti-APP N-terminal,
mouse IgG1, 1 mg/ml, Milipore, Billerica, MA), 4G8 anti-
Ab residues 17-24, mouse IgG, Senetek, Maryland Height,
MD), CT1565 (anti-APP C-terminal, rabbit monoclonal
#1565, 0.45 mg/ml, Epitomics, Burlingame, CA), CT695
(anti-APP C-terminal, rabbit polyclonal #51-2700, 0.25
mg/ml, Invitrogen, Carlsbad, CA), anti-Ab40 (MM32-
13.1.1, mouse IgG1, 1.8 mg/ml, Bu lab), anti-Ab42 (rabbit,
0.35 mg/ml; Invitrogen, Carlsbad, CA), anti-b-actin
(chicken, 1.0 mg/ml; Abcam, Cambridge MA) cathepsin-D
(goat polyclonal, 0.2 mg/ml, Santa Cruz biotechnology,
Santa Cruz, CA). The dilutions of each antibody stock are
denoted in the appropriate Methods section or Figure
Legend.
Ab peptide arrays
A peptide array (PepSpotsTM) consisting of a series of
overlapping 10-mers from the -4 position of the Ab
sequence to residue 46 covalently bonded via the carboxyl
terminus to a cellulose membrane was prepared by JPT
Peptide Technologies, GmbH, Berlin, Germany and used
according to the manufacturer’s recommendations (gener-
ously provided by C. Glabe). Membranes (n = 3) were
incubated with 100 ng/ml of MOAB-2 or IgG2b isotype
matched control (Sigma-Aldrich, St. Louis, MO) and then
rabbit-anti-mouse antibody conjugated with HRP and
visualized with ECL substrate.
Tissue preparation
For in vitro analysis of APP, cortex samples were extracted
and homogenized as described [38]. 3xTg mouse tissue
was obtained from F. LaFerla, University of California,
Irvine CA. 5xFAD/BACE
-/- tissues were obtained from R.
Vassar, Northwestern University, Chicago, IL.
The in vivo experiments described below follow either
the Rush University Medical Center Institutional Animal
Care and Use Committee protocols, or the UIC Institu-
tional Animal Care and Use Committee protocols.
IHC -DAB protocol (these experiment were conducted at
Rush University Medical Center)
Mice are housed under standard conditions with access
to food and water ad libitum.1 - ,2 - ,a n d4 - m o n t ho l d
5xFAD mice and were anesthetized with a single injection
of ketamine/xylazine (100 mg/kg/5.0 mg/kg) and transcar-
dially perfused with 0.9% saline for 2 min followed 4%
paraformaldehyde and 0.1% glutaraldehyde made in 0.1 M
phosphate buffer (PB) for 4 min. Brains were removed and
dissected at the midline. The right hemibrains were post-
fixed in the same fixative for 24 hours at 4°C and then
stored in 30% sucrose at 4°C. Hemibrains were frozen on
dry ice and coronal sections were cut immediately at
40 μm thickness on a sliding microtome. Sections were
stored in cryoprotectant (30% glycerin, 30% ethylene gly-
col, in 0.1 M PB) at -20°C until analysis.
IHC -fluorescence protocol (these experiments were
conducted at UIC)
Mice were anesthetized with sodium pentobarbital (50
mg/kg) and transcardially perfused with ice-cold PBS +
Protease Inhibitor Cocktail (Calbiochem, set 3). Directly
following perfusion, brains were removed and dissected at
the midline. Left hemibrains from mice at each age were
drop-fixed in 4% paraformaldehyde (PFA) for 48 hrs fol-
lowed by storage at 4°C in phosphate buffered saline (PBS)
+ 0.05% sodium azide (NaN3) until use. Prior to IHC,
hemi-brains were dehydrated in 30% sucrose for 48 hours.
For tissue homogenization: Right hemibrains were
rapidly dissected on ice into cortex (CX), hippocampus
(H) and cerebellum (CB), immediately snap frozen in
liquid nitrogen, and stored at -80°C until use.
Cell culture
HEK-APPSwe/BACE1 cells (obtained from R.Vassar,
Northwestern University, Chicago, IL) [37] were grown
to confluence in DMEM medium supplement with 10%
fetal bovine serum and 100 μg/ml of G418. Cells were
washed twice with 1xPBS, and grown in DMEM medium
for another 3 days. The conditioned medium was col-
lected, and cell lysates were prepared in 1xRIPA buffer
(Sigma-Aldrich) supplemented with 1x protease inhibitor
mix (Calbiochem).
Dot- and western-blot analyses
Gel electrophoresis and Western blot analyses were per-
formed according to manufacturer’s protocols (Invitrogen)
as previously described [32,33]. Briefly, samples in lithium
dodecyl sulphate (LDS) sample buffer (Invitrogen) were
heated to 90°C for 5 minutes and loaded into wells of 12%
or 4-12% Bis-TRIS NuPAGE gels, electrophoresed using
MES running buffer and transferred to 0.45 μmP V D F
membranes (Invitrogen). Membranes were blocked in 5%
non-fat dry milk in Tris-buffered saline containing
0.0625% Tween-20 (TBST), and incubated in primary fol-
lowed by HRP-conjugated secondary antibodies (1:5000
dilution of 0.8 mg/ml stocks, Jackson Immunoresearch,
West Grove, PA). For in vitro analyses, the following anti-
body dilutions were used (unless otherwise noted on
Figure or in Figure Legend): MOAB-2 (1:5000), 6E10
(1:5000), CT1565 (1:2500), 22C11 (1:500), and b-actin
(1:5000). Immunoreactivity was detected using enhanced
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imaged on a Kodak Image Station 4000R. Molecular
weight values were estimated using pre-stained molecular
weight markers. For dot-blots samples were loaded onto
0.45 μm PVDF membranes through wells of a dot-blot
apparatus, and washed with TBST buffer. All subsequent
blocking and antibody incubation steps were performed as
described for Western blot analysis. The amount of each
Ab peptide, cell lysates or tissue homogenate is specified
on the appropriate Figure or in the Figure Legend.
Immunoprecipitation
0.5 pmol of U- and O-Ab42 were diluted in TBST buf-
fer. Protein A/G agarose beads (UltraLink Immobilized
Protein A/G, Pierce) was added to pre-clear non-specific
association with the beads. 10 μl of 0.5 mg/ml MOAB-2
or 6E10 antibodies were incubated with Ab42 at 4°C
overnight. Protein A/G agarose beads were added for an
additional 2 hr. After a brief centrifugation, the pellets
of Ab42/antibody/Protein A/G complex were washed
thoroughly with TBST buffer at 4°C, and boiled for
5 min in 1xLDS buffer with 5% b-mercaptoethanol.
Released Ab42 was separated in 12.5% NuPAGE, 0.025
pmol and 0.05 pmol of Ab42 were also included to
gauge the immunoprecipitation efficiency. Ab42 were
analyzed by Western blotting with biotinylated 4G8
antibody/StreptAvidin-HRP pair and visualized by ECL
(SuperSignal West Dura, Thermo Scientific), the gel
image was captured by Kodak Image Station 4000R.
Solid plate binding assay
MOAB-2 binding to Ab was assessed by a solid plate bind-
ing assay as previously described [61]. 25 ng of U-, O-, and
F-Ab42 were immobilized onto microtiter plate wells in
PBS for 2 hr. All the incubation steps were performed at
37°C. The wells were then blocked with 1% BSA in PBS
for 1 hr, incubated for 1 hr with the primary antibody
(MOAB2/control IgG), washed, and incubated for 1 hr
with a biotinylated anti-IgG antibody. The binding was
quantified by incubation with a streptavidin-Eu conjugate,
measured by time resolved Eu-fluorescence and converted
into fmols of biotin. Negative control (binding to BSA cov-
ered wells, with no Ab) was subtracted from all the bind-
ing curves. EC50 values were calculated using non-linear
curve fitting, GraphPad Prism version 4.00, GraphPad
Software, San Diego California USA.
Immunohistochemical analysis: Diaminobenzidine staining
Note: Initial characterization of MOAB-2 by IHC demon-
strated no significant differences in Ab detection using
paraffin and free-floating sections (Bu and LaDu lab, data
not shown). Formic acid (FA) treatment resulted in opti-
mal detection of both intraneuronal and extracellular Ab
compared to without FA. This is consistent with data
from Christensen and co-workers who demonstrated that
FA was essential for IHC detection of aggregated intra-
neuronal Ab in mouse models of AD, including 5xFAD
[27]. Thus, FA was used for both DAB and immunofluor-
escent, as described below.
Tissues from 1- and 3-month old 5xFAD mice were pro-
cessed as free-floating sections and immunostained using
the mouse monoclonal antibodies 6E10 (1:1000) and
MOAB-2 (1:550). All procedures were conducted at room
temperature, except primary antibody incubation was
done at 4°C. Briefly, 40 μm-thick coronal sections were
r i n s e di n0 . 1MP B S( 3×1 0m i n ) ,w a s h e di nT B S( 3×
10 min), incubated in 88% FA (8 min) for antigen retrieval
[28], washed (TBS, 3 × 10 min) and incubated in 0.1 M
sodium metaperiodate (20 min; Sigma-Aldrich) to quench
endogenous peroxidase activity. Tissue sections were per-
meabilized in TBS containing 0.25% Triton X-100 (TBSX;
3 × 10 min), blocked with 3% horse serum in TBSX (3 ×
10 min) followed by 1% horse serum in TBSX (2 ×
10 min) and incubated with appropriate primary antibo-
dies diluted in TBSX containing 1% horse serum over-
night. Subsequently, sections were washed (1% horse
serum, 3 × 10 min) incubated with biotinylated secondary
antibody (anti-mouse IgG; 1:200, 1 hr Room temperature)
washed (TBS 3 × 10 min) and then incubated with avidin-
biotin complex (1:500; Elite Kit, Vector Labs) for 1 hr. Sec-
tions were washed in a 0.2 M sodium acetate trihydrate
and 1.0 M imidazole solution (pH 7.4 with acetic acid; 3 ×
10 min). Reaction products were visualized using an acet-
ate-imidazole buffer containing 0.05% 3/3’-diaminobenzi-
dine tetrahydrochloride (DAB; Sigma, MO) and 0.0015%
hydrogen peroxide. For comparison purposes, sections
immunostained with the same antibody were incubated in
DAB for the same duration. Sections were then washed in
acetate-imidazole buffer (3 × 5 min), transferred to TBS,
mounted onto glass slides, air dried overnight, dehydrated
through a series of graded alcohols (70%, 95%, 100%; 3 ×
5 min), cleared in xylene (3 × 5 min) and cover-slipped
with DPX (BDH Laboratory Supplies, Poole, UK).
Immunohistochemical analysis: Immunofluorescent
microscopy
Tissues were processed as outlined above, washed in TBS
(3 × 10 min), incubated in 88% FA (8 min), permeabilized
in TBSX (3 × 10 min), and blocked in TBSX containing
5% bovine serum albumin (BSA; 1 hr). Sections were sub-
sequently incubated with appropriate primary antibodies
diluted in TBSX containing 2% BSA overnight on an oscil-
latory rotator. For IHC analyses, the following primary
antibodies were used: MOAB-2 (1:1000), anti-Ab40,
(1:1700), anti-Ab42 (1:200), 22C11 (1:40), CT695 (1:500),
6E10 (1:1000) and cathepsin-D (1:50). The following day,
sections were washed in TBSX (6 × 10 min), followed by
Alexa fluorophore-conjugated secondary antibodies
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ger M1 under identical capture settings, at 20× or 63×
magnification (as indicated) or at 100× with a Zeiss LSM
510 confocal microscope.
Additional material
Additional file 1: Figure S1. MOAB-2 epitope mapping. (A) Peptide
array (PepSpots™™) consisting of a series of overlapping 10-mers from
the -4 position of the Ab sequence to residue 46. Membranes were
incubated with MOAB-2 or IgG2b control antibody (1:2000 dilution from
0.2 mg/ml stock). Image representative of n = 3. (B) Dot blot of serial
dilutions of rat (R) Ab, human (H) Ab40 and human Ab42 probed with
MOAB-2. Antibody concentration for MOAB-2 = 100 ng/ml (1:5000
dilution).
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